Compare JAZZ & SGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | SGI |
|---|---|---|
| Founded | 2003 | 1846 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.3B |
| IPO Year | 2007 | 2003 |
| Metric | JAZZ | SGI |
|---|---|---|
| Price | $242.66 | $60.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $297.50 | $85.40 |
| AVG Volume (30 Days) | 691.1K | ★ 3.1M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.04 | ★ 1.76 |
| Revenue | $1,618,693,000.00 | ★ $2,754,400,000.00 |
| Revenue This Year | $12.68 | $15.75 |
| Revenue Next Year | $5.34 | $29.47 |
| P/E Ratio | $6,014.25 | ★ $33.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $156.95 | $57.94 |
| 52 Week High | $266.38 | $98.56 |
| Indicator | JAZZ | SGI |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 42.66 |
| Support Level | $236.70 | N/A |
| Resistance Level | $250.49 | $71.33 |
| Average True Range (ATR) | 7.43 | 2.96 |
| MACD | 2.04 | -0.70 |
| Stochastic Oscillator | 81.96 | 17.60 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses Mattress Firm, Tempur Sealy North America and Tempur Sealy International. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.